Streetwise Reports' Article Archives — June 2020 back to current month (32)
Algernon Pharmaceuticals is seeking approved participation from Australia, Romania and the Philippines as well.
Avivagen reported it received approval for use of OxC-beta™ Livestock in Brazil and it has signed an agreement with a São Paulo company for distribution.
Shares of Vaxart Inc. nearly doubled after the company reported that it has signed a Memorandum of Understanding with Attwill Medical Solutions Sterilflow to enable production of a billion or more tablet COVID-19 vaccine doses annually.
These results of a study evaluating Targovax's lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report.
With this transaction, CloudMD Software & Services expands its size and reach.
Translate Bio shares traded 45% higher reaching a new 52-week high after the company reported that it is expanding its collaboration with Sanofi Pasteur to develop mRNA vaccines across all infectious disease areas.
Shares of Invitae Corp. traded 40% higher after the company reported it will acquire ArcherDX in a combination cash and stock deal valued at around $1.4 billion.
Ampio Pharmaceuticals' shares traded higher after the company reported that the FDA cleared the firm to proceed with human trials of its Investigative New Drug application for intravenous AmpionTM for treatment in COVID-19 affected patients on supplemental oxygen.
Shares of Alpine Immune Sciences set a new 52-week high after the company reported that it entered into an exclusive worldwide option and license agreement with AbbVie Inc. to develop and commercialize ALPN-101.
Pluristem Therapeutics' coronavirus clinical studies and financing are discussed in a Dawson James report.
The design, timeline and takeaways of Beyond Air's study are presented in a ROTH Capital Partners report.
ProMIS Neurosciences states that the current version of the ProMIS-BCNI assay achieves 99.9% sensitivity and 99.5% specificity for SARS CoV-2, the coronavirus causing COVID-19.
Eli Lilly shares set a new 52-week high price after the company reported that its Verzenio® (abemaciclib) significantly reduced the risk of cancer returning in people with high risk HR+, HER2- early breast cancer.
CloudMD reported that it has signed a binding agreement to acquire a British Columbia medical clinic with 12 on-staff physicians in a cash and stock deal valued at CA$700,000.
Revive Therapeutics Ltd. reported it has expanded its research partnership for novel formulation development and clinical research of psilocybin with the University of Wisconsin-Madison.
Shares of Edesa Biotech traded more than 100% higher after the company reported that it had received regulatory approval from Health Canada to initiate a Phase 2/3 study of its investigational drug EB05 in COVID-19.
Shares of Reata Pharmaceuticals traded 30% higher after reporting that Blackstone Life Sciences will invest $350 million in the company to advance bardoxolone methyl as a potential therapy for Alport syndrome and other rare and serious chronic kidney diseases.
Revive Therapeutics met with Health Canada to discuss how best to proceed.
Curis Inc. shares are up more than 130% and established a new 52-week high price after reporting that the FDA cleared the company's IND Application for CI-8993, its monoclonal anti-VISTA antibody.
A review of CloudMD Software & Services and the reasons why it makes a compelling investment are provided in a Beacon Securities report.
Shares of Enochian Biosciences reached a new 52-week high after the company reported that it successfully completed its FDA INTERACT meeting for ENOB-HV-01, a potential cure for HIV.
Aurora Cannabis 'Upside Breakout Looks Imminent' (06/08/2020)
Technical analyst Clive Maund charts the cannabis company and explains why he calls it an "immediate strong buy."
Mackie Research believes Blockchain Holdings' TraceSafe tracking platform could tap into the "exceptionally large market" for contact tracing during the Covid-19 pandemic.
Algernon Pharmaceuticals prepares to commence the Phase 2b study as soon as possible.
Revive Therapeutics is focused on infectious diseases as well as treatments using psilocybin-based formulations.
Telemedicine Firm Achieves Record Revenue in Q1/20 (06/03/2020)
Also during the quarter, CloudMD Software & Services completes an acquisition, releases an app and upgrades its stock listing.
COVID-19: A Catalyst for Small-Cap Outperformance (06/03/2020)
Steve Palmer, president and chief investment officer of AlphaNorth Asset Management, outlines why he believes Canadian companies on the TSX Venture Index remain good investments in a time of pandemic uncertainty.
Recently presented results from Enlivex Therapeutics' Phase 1b study in sepsis and their implications are reviewed in an H.C. Wainwright & Co. report.
Xtract AI has secured a CA$150,000 grant from the Innovative Solutions Canada program to utilize artificial intelligence to increase organ donations and improve transplant success rates.
Shares of Cassava Sciences traded 70% higher after the firm provided updates from its Phase 2b study of PTI-125 for use in treating Alzheimer' disease.
Demand for Reliq Health Technologies' offerings continues to grow due to the COVID-19 pandemic.
Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids.
|"PMN's upside is relatively unlimited; it is rated an Immediate Buy."|